Thymectomy Bests Medical Therapy in Myasthenia Gravis Thymectomy Bests Medical Therapy in Myasthenia Gravis
' The trial ends an 80-year controversy'about benefits of thymectomy for patients with major myasthenia gravis but no thymus tumor, experts say.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 11, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

NIH-funded study supports surgery as treatment for myasthenia gravis
Autoimmune disease causes muscle weakness and fatigue. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 11, 2016 Category: American Health Source Type: news

Surgery Effective Against Immune Disorder That Weakens Muscles
THURSDAY, Aug. 11, 2016 -- Removing the thymus gland is an effective treatment for myasthenia gravis, an autoimmune disorder that causes life-threatening muscle weakness, researchers report. Since the 1940s, doctors have been surgically removing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 11, 2016 Category: Journals (General) Source Type: news

Thymectomy improves clinical outcomes for myasthenia gravis
Thymectomy improved 3-year clinical outcomes and proved superior to medical therapy for mild to severe nonthymomatous myasthenia gravis, according to a report published online Aug. 11 in the New... (Source: Family Practice News)
Source: Family Practice News - August 10, 2016 Category: Primary Care Source Type: news

NIH-funded study supports surgery as treatment for myasthenia gravis
In a global study of myasthenia gravis, an autoimmune disease that causes muscle weakness and fatigue, researchers found that surgical removal of an organ called the thymus reduced patients ’ weakness, and their need for immunosuppressive drugs. The study, published in the New England Journal of Medicine, was partially funded by the National Institutes of Health. (Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke)
Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke - August 10, 2016 Category: Neurology Source Type: news

New Consensus Guidance on Myasthenia Gravis New Consensus Guidance on Myasthenia Gravis
The new international expert consensus is intended to be a guide for clinicians caring for patients with myasthenia gravis worldwide. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Success With Stem Cell Transplant in Myasthenia Gravis Success With Stem Cell Transplant in Myasthenia Gravis
Seven patients with severe myasthenia gravis who received autologous hematopoietic stem cell transplants have experienced long-term remission. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 4, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

What it’s like to be in neurology: Shadowing Dr. Govindarajan
As a medical student, do you ever wonder what it’s like to be a neurologist? Here’s your chance to find out. Meet Raghav Govindarajan, MD, a neurologist and featured physician in AMA Wire’s® “Shadow Me” Specialty Series, which offers advice directly from physicians about life in their specialties. Read his insights to help determine whether a career in neurology might be a good fit for you. "Shadowing" Dr. Govindarajan Specialty: Neurology Practice setting: University hospital Years in practice: 2 A typical week in my practice: I am a neurologist with special...
Source: AMA Wire - April 19, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news

What it ’s like to be in neurology: Shadowing Dr. Govindarajan
As a medical student, do you ever wonder what it ’s like to be a neurologist? Here’s your chance to find out. Meet Raghav Govindarajan, MD, a neurologist and featured physician in AMA Wire ’s ® “Shadow Me” Specialty Series , which offers advice directly from physicians about life in their specialties. Read his insights to help determine whether a career in neurology might be a good fit for you. " Shadowing " Dr.  Govindarajan Specialty: Neurology Practice setting: University hospital Years in practice: 2 A typical week in my practice: I am a neurologist wit...
Source: AMA Wire - April 19, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis
Study findings in seven patients with severe myasthenia gravis support the use of autologous haematopoietic stem cell transplantation for achieving long-term remission. (Source: MedWire News)
Source: MedWire News - April 6, 2016 Category: Consumer Health News Tags: Neurology Source Type: news

Stem Cell Therapy May Work in Severe Myasthenia Gravis (CME/CE)
(MedPage Today) -- Small single-center study supports autologous stem cell transplant for severe myasthenia gravis (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 6, 2016 Category: Neurology Source Type: news

Study examines impact of 2 new antibodies in causing, treating myasthenia gravis
(Medical College of Georgia at Augusta University) A study of patients from across the nation with myasthenia gravis is helping determine the incidence of two new antibodies believed to cause the disease, and whether these patients need different treatment strategies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2016 Category: Global & Universal Source Type: news

Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
CORAL GABLES, Fla., Feb. 17, 2016 -- (Healthcare Sales & Marketing Network) -- Catalyst Pharmaceuticals, Inc. (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, tod... Biopharmaceuticals, FDACatalyst Pharmaceuticals, Firdapse, amifampridine, Lambert Eaton Myasthenic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 17, 2016 Category: Pharmaceuticals Source Type: news

Lambert-Eaton Syndrome: Causes, Symptoms & Treatments
Lambert-Eaton syndrome also known as, 'Lambert-Eaton myasthenic syndrome,' is a condition in which a person's immune system attacks their neuromuscular junctions, the areas where your nerves and muscles connect. Usually a person's nerve cells pass signals along to their muscles. The signals help to make your muscles move. Due to the fact that Lambert-Eaton syndrome affects the way a person's nerves and muscles communicate, moving muscles becomes difficult. (Source: Disabled World)
Source: Disabled World - December 27, 2015 Category: Disability Tags: Autoimmune Diseases Source Type: news

Catalyst Pharmaceuticals Completes NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes
CORAL GABLES, Fla., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 17, 2015 Category: Drugs & Pharmacology Source Type: news

ARJ Infusion Services, Lonnie Kersey Receives Prestigious Award from...
Myasthenia Gravis Association of Kansas City presented Lonnie Kersey the “Stackhouse Distinguished Service Award”. It's the organization's most prominent award of the year.(PRWeb November 12, 2015)Read the full story at http://www.prweb.com/releases/2015/11/prweb13075792.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 13, 2015 Category: Pharmaceuticals Source Type: news

Orphan Drug Shown Effective for LEMS WeaknessOrphan Drug Shown Effective for LEMS Weakness
The study was designed to finally earn FDA approval for 3,4 DAP, long used to treat Lambert-Eaton myasthenic syndrome on a compassionate basis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 7, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

FDA panel recommends limited use of Bayer’s Essure until more is known about safety
An FDA advisory panel yesterday recommended that the agency limit the use of Bayer‘s (ETR:BAYN) Essure female sterilization device until more is known about its safety, after thousands of women reported serious health issues they attribute to the nickel-titanium implant. Essure, the only approved permanent birth control device in the U.S., is a small metal coil that is placed in the fallopian tubes via catheter. The FDA approved the device in November 2002. In the near 13 years since then, the health regulator said it had received 5,093 complaints, including those of pain or menstrual irregularities af...
Source: Mass Device - September 25, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Women's Health Bayer HealthCare Obstetrics and Gynecology Devices Advisory Panel Source Type: news

The Emerging Role of Tacrolimus in Myasthenia GravisThe Emerging Role of Tacrolimus in Myasthenia Gravis
Is the immunosuppressive drug tacrolimus beneficial in reducing symptoms of myasthenia gravis? This review summarizes the latest evidence. Therapeutic Advances in Neurological Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 26, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Pediatric Patient Loses Spontaneous Respirations
Matthew, a 6-year-old male, has been feeling increasingly short of breath throughout the course of the morning. His father also notices that over the last several days he’s been appearing increasingly tired with a cough. Matthew is watching TV on the floor in the living room when his father enters the room and finds him unresponsive and apneic. He calls 9-1-1. The Call Paramedics respond immediately, but the response is uneventful. They arrive on scene and are met outside by the patient’s father, who takes them into the house and tells them his son has been feeling ill over the past several days but wasn’...
Source: JEMS Special Topics - March 11, 2015 Category: Emergency Medicine Authors: Elizabeth K. Powell, MD Tags: Case of the Month Pediatrics Airway & Respiratory Source Type: news

Score in Development to Detect Myasthenia Gravis WorseningScore in Development to Detect Myasthenia Gravis Worsening
A scoring system can help predict the risk for conversion from ocular myasthenia gravis to generalized disease, a new study has shown. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

New Diagnostic Test Proposed for Myasthenia GravisNew Diagnostic Test Proposed for Myasthenia Gravis
Ocular vestibular-evoked myogenic potentials could be used to diagnose myasthenia gravis, researchers report. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 25, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Myasthenia Gravis Therapeutic Pipeline Drugs and Companies Review H2...
RnRMarketResearch.com adds Myasthenia Gravis Pipeline Review H2 2014 to its store. The report provides an overview of the Myasthenia Gravis therapeutic pipeline.(PRWeb December 15, 2014)Read the full story at http://www.prweb.com/releases/2014-h2-myasthenia-gravis/pipeline-review-market/prweb12395670.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 16, 2014 Category: Pharmaceuticals Source Type: news

High prevalence of vitamin D deficiency across the board in neuromuscular disease
More credence has been added to a growing awareness of the high prevalence of vitamin D deficiency in neuromuscular disease by newly presented research. Vitamin D supplementation has been suggested to improve function in frail elderly patients at risk for falls, as well as individuals with myasthenia gravis and Parkinson's. The impact of vitamin D deficiency and supplementation on function in other neurologic conditions has yet to be explored. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 31, 2014 Category: Science Source Type: news

Efficacy of potential therapy for autoimmune disorder of muscle weakness
(University of Pennsylvania School of Medicine) Researchers have made a fast-acting 'vaccine' that can reverse the course of myasthenia gravis, a non-inherited autoimmune form of muscle weakness, in an animal model of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 7, 2014 Category: Global & Universal Source Type: news

Amy Guy can't move facial muscles due to incurable condition that's killing her muscles
Amy Guy, 34, from Southampton, has Myasthenia gravis. The condition causes certain muscles - including those that control facial expression - to become weak. (Source: the Mail online | Health)
Source: the Mail online | Health - October 3, 2014 Category: Consumer Health News Source Type: news

Alexion receives orphan drug designation for Soliris in Europe
The European Commission has granted orphan drug designation to Alexion Pharmaceuticals’ Soliris (eculizumab), a terminal complement inhibitor, to treat patients with myasthenia gravis (MG). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 5, 2014 Category: Pharmaceuticals Source Type: news

European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
CHESHIRE, Conn.--(Healthcare Sales & Marketing Network)--Alexion Pharmaceuticals (ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis... Biopharmaceuticals, RegulatoryAlexion Pharmaceuticals, Soliris, eculizumab, Myasthenia Gravis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 1, 2014 Category: Pharmaceuticals Source Type: news

Therapeutic Options for Juvenile Myasthenia GravisTherapeutic Options for Juvenile Myasthenia Gravis
The outcomes with plasmapheresis and IVIG as maintenance therapies are compared in a 33-year retrospective analysis. Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Mitochondrial Mutation Linked to Congenital Myasthenic Syndrome
Although significant progress has been made over the last 25 years to identify genetic abnormalities associated with congenital myasthenic syndromes (CMS), many patients remain genetically undiagnosed. A report now identifies a gene defect in mitochondria, specifically the citrate carrier SLC25A1, that may underlie deficits in neuromuscular transmission seen in two siblings. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 20, 2014 Category: Science Source Type: news

Researchers identify mitochondrial mutation linked to congenital myasthenic syndrome
(IOS Press) Although significant progress has been made over the last 25 years to identify genetic abnormalities associated with congenital myasthenic syndromes (CMS), many patients remain genetically undiagnosed. A report in the inaugural issue of the Journal of Neuromuscular Diseases identifies a gene defect in mitochondria, specifically the citrate carrier SLC25A1, that may underlie deficits in neuromuscular transmission seen in two siblings. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 20, 2014 Category: Global & Universal Source Type: news

June is Myasthenia Gravis Awareness Month
. Visit the Myasthenia gravis topic page, which includes an interactive tutorial. (Source: What's New on MedlinePlus)
Source: What's New on MedlinePlus - June 18, 2014 Category: Consumer Health News Source Type: news

2 Cases of Myasthenia Gravis Seen With Ipilimumab2 Cases of Myasthenia Gravis Seen With Ipilimumab
The autoimmune neuromuscular disorder is now associated with this new treatment for metastatic melanoma. Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 1, 2014 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Two Cases of Myasthenia Gravis Seen With IpilimumabTwo Cases of Myasthenia Gravis Seen With Ipilimumab
The autoimmune neuromuscular disorder is now associated with this new treatment for metastatic melanoma. Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 30, 2014 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Catalyst closes patient enrolment in Phase III LEMS trial
US-based Catalyst Pharmaceutical Partners has completed patient enrolment in a Phase III trial assessing the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). (Source: Drug Development Technology)
Source: Drug Development Technology - April 3, 2014 Category: Pharmaceuticals Source Type: news

Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)
Barrett S. McGrath Named as Chief Commercial Officer CORAL GABLES, Fla., March 28, 2014 -- (Healthcare Sales & Marketing Network) -- Catalyst Pharmaceutical Partners, Inc. (CPRX), a specialty pharmaceutical company focused on developing safe and effecti... Biopharmaceuticals, Neurology, PersonnelCatalyst Pharmaceutical, Firdapse, Lambert-Eaton Myasthenic Syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2014 Category: Pharmaceuticals Source Type: news

PLEX and IVIG Effective Maintenance Options in Juvenile MGPLEX and IVIG Effective Maintenance Options in Juvenile MG
Plasmapheresis (PLEX) and intravenous immunoglobulin (IVIG) are both "reasonable" maintenance therapy options for juvenile myasthenia gravis, although responses may be more consistent with PLEX. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 6, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

What Causes Muscle Weakness?
Discussion Muscle tone is the slight tension that is felt in a muscle when it is voluntarily relaxed. It can be assessed by asking the patient to relax and then taking the muscles through a range of motion such as moving the wrists, forearm and upper arm. Muscle strength is the muscle’s force against active resistance. Impaired strength is called weakness or paresis. There are 5 levels of muscle strength. 0 = No muscle contraction detected 1 = Barely detected flicker of contraction 2 = Active movement with gravity eliminated 3 = Active movement against gravity 4 = Active movement against gravity and some resistance ...
Source: PediatricEducation.org - December 9, 2013 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

New technique for testing drugs to treat cystic fibrosis and epilepsy
Researchers from the University of Southampton, in collaboration with researchers at the University of Quebec at Montreal, have developed a new microsystem for more efficient testing of pharmaceutical drugs to treat diseases such as cystic fibrosis, MG (myasthenia gravis) and epilepsy.A large percentage of pharmaceutical drugs target ion channels, which are proteins found in a cell's membrane, that play a pivotal role in these serious disorders and that are used to test the effectiveness of new drugs. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 30, 2013 Category: Consumer Health News Tags: Pharma Industry / Biotech Industry Source Type: news

Discovery of most common cause of muscle-weakening disease myasthenia gravis
An antibody to a protein critical to enabling the brain to talk to muscles has been identified as a cause of myasthenia gravis, researchers report. The finding that an antibody to LRP4 is a cause of the most common disease affecting brain-muscle interaction helps explain why as many as 10 percent of patients have classic symptoms, like drooping eyelids and generalized muscle weakness, yet their blood provides no clue of the cause, said Dr. Lin Mei, Director of the Institute of Molecular Medicine and Genetics at the Medical College of Georgia at Georgia Regents University... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 13, 2013 Category: Consumer Health News Tags: Muscular Dystrophy / ALS Source Type: news

New cause found for muscle-weakening disease myasthenia gravis
(Medical College of Georgia at Georgia Regents University) An antibody to a protein critical to enabling the brain to talk to muscles has been identified as a cause of myasthenia gravis, researchers report. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 11, 2013 Category: Global & Universal Source Type: news

JCI early table of contents for Nov. 8, 2013
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Nov., 8, 2013, in the JCI: Ion channel inhibition limits injury-induced loss of kidney filtration, Researchers identify a histone demethylase associated with non-small cell lung cancer,Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis, Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy, Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma, and more....
Source: EurekAlert! - Medicine and Health - November 8, 2013 Category: Global & Universal Source Type: news

Late-Onset Myasthenia Gravis Linked to Higher Cancer RiskLate-Onset Myasthenia Gravis Linked to Higher Cancer Risk
Myasthenia gravis, especially if it is of late onset, carries a high risk for cancers outside of the thymus. These malignancies were of heterogeneous origin, and all were solid tumors, a study shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Myasthenia Gravis May Follow Infection by West Nile VirusMyasthenia Gravis May Follow Infection by West Nile Virus
West Nile virus infection is now linked to myasthenia gravis months later, case reports indicate. Residual deficits, such as weakness or fatigue, may confound or delay the myasthenia gravis diagnosis. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

How Often Does Clubfoot Recur?
Discussion Newborn foot deformities are relatively common with an incidence of ~4.2%. About 75% of these are due to metatarsus adductus. Talipes equinovarus, calcaneovulgus foot and vertical talus are the other most common abnormalities. Congenital talipes equinovarus or clubfoot deformity occurs in 1-2/1000 births. The mneumonic CAVE identifies the major findings of Cavus, forefoot Adduction, hindfoot Varus and Equinus. Clubfoot can be mild to severe with the more severe forms being associated with other problems. The Ponseti method is currently considered the main treatment method with better short-term outcomes compar...
Source: PediatricEducation.org - May 6, 2013 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: news

Tirasemtiv: Initial Promise in Myasthenia Gravis Tirasemtiv: Initial Promise in Myasthenia Gravis
Results of a pilot trial suggest that the drug, which is also being studied in ALS, may improve function in myasthenia gravis. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy - Kluger BM, Krupp LB, Enoka RM.
Fatigue is commonly reported in many neurologic illnesses, including multiple sclerosis, Parkinson disease, myasthenia gravis, traumatic brain injury, and stroke. Fatigue contributes substantially to decrements in quality of life and disability in these il... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - January 25, 2013 Category: Global & Universal Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

Clinical Review: Myasthenia gravis
The characteristics of myasthenia gravis, key diagnostic features and how to manage this condition, aplus a round up of the current evidence base. (Source: GP Online Education)
Source: GP Online Education - April 29, 2011 Category: Primary Care Tags: Autoimmune disorders Source Type: news